ReviewLiver cancer2024
Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma.
Review in Liver cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 26 citations in OpenAlex.
- Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Laparoscopic liver resection for patients with intrahepatic cholangiocarcinoma using data from the Japanese National Database: A nationwide observational study.Global health & medicine · 2026Article
- [Preparation of retinoic acid and irinotecan co-loaded lipo-somes and theirZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026Article
- Gemcitabine-cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma: effectiveness outcomes and characterization of the tumor microenvironment.Hepatology international · 2026Article
- A pyroptosis-related molecular signature stratifies prognosis and highlights GSDMB-mediated malignancy in intrahepatic cholangiocarcinoma.Biology direct · 2026Article
- NRXN3 regulates pyroptosis in intrahepatic cholangiocarcinoma via mediating the phospho-dependent ubiquitination and degradation of caspase-3.Journal of advanced research · 2026Article
- Article
- A pathomics-integrated multimodal model to evaluate chemoimmunotherapy efficacy in unresectable intrahepatic cholangiocarcinoma.JHEP reports : innovation in hepatology · 2025Article
- MUC1 drives ferroptosis resistance in ICC via Src-mediated FSP1 deubiquitination and myristoylation.Clinical and translational medicine · 2025Article
- Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target.Clinical and molecular hepatology · 2025Article
- Predicting cisplatin response in cholangiocarcinoma patients using chromosome pattern and related gene expression.Scientific reports · 2025Article
- Impact of postoperative chemotherapy on the prognosis of combined hepatocellular-cholangiocarcinoma: a retrospective study based on the SEER database.Journal of gastrointestinal oncology · 2025Article
- Genomic landscape of biliary tract cancer and corresponding targeted treatment strategies.International journal of clinical oncology · 2025Review
- Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges.World journal of gastroenterology · 2025Review
- Cystatin B Promotes the Proliferation, Migration, and Invasion of Intrahepatic Cholangiocarcinoma.Current oncology (Toronto, Ont.) · 2025Article
- Systemic therapy with pemigatinib and sintilimab followed by resection for recurrent FGFR-2-positive intrahepatic cholangiocarcinoma: a case report.Frontiers in oncology · 2025Article
- Serum 25-Hydroxyvitamin D Levels and Survival Outcomes in Advanced Biliary Tract Cancer: Results From the NIFTY Trial.Cancer medicine · 2025Article
- Incidence and Long-Term Outcomes of Biliary Tract Cancers in Olmsted County, Minnesota from 1976 to 2018.Cancers · 2024Article
- Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma.Cell death & disease · 2024Article
- Response to trametinib, hydroxychloroquine, and bevacizumab in a young woman withExploration of targeted anti-tumor therapy · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of intrahepatic cholangiocarcinoma (IHCCA) is rising around the world. The disease is becoming a major global health issue. Conventionally, most patients with cholangiocarcinoma present with advanced disease and systemic therapy is the mainstay of treatment. This review discusses recent advances in systemic treatments for patients with IHCCA. Summary: The addition of durvalumab to a gemcitabine plus cisplatin regimen has significantly improved overall survival in the phase 3 TOPAZ-1 trial and is currently recommended as a standard first-line treatment. The phase 3 ABC-06 and phase 2b NIFTY trials have shown the benefit of second-line fluoropyrimidine plus oxaliplatin, and fluoropyrimidine plus nanoliposomal irinotecan, respectively. They have provided a treatment option for patients without actionable alterations who progressed to first-line therapy. For patients with actionable genomic alterations, including Key Messages: Recent advances in systemic treatments have improved clinical outcomes in patients with advanced IHCCA. However, most patients eventually show resistance to the treatment, and tumor progression occurs within a year. Indeed, there should be further efforts to improve the outcomes of patients with advanced IHCCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.